Janus Henderson Group PLC lowered its holdings in Nevro Corp. (NYSE:NVRO) by 12.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,249,367 shares of the medical equipment provider’s stock after selling 172,600 shares during the quarter. Janus Henderson Group PLC owned 4.22% of Nevro worth $113,542,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of NVRO. Bank of Montreal Can grew its stake in Nevro by 36.6% during the second quarter. Bank of Montreal Can now owns 13,187 shares of the medical equipment provider’s stock worth $982,000 after buying an additional 3,534 shares during the last quarter. US Bancorp DE grew its stake in Nevro by 412.4% during the second quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock worth $194,000 after buying an additional 2,099 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Nevro by 12.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 106,598 shares of the medical equipment provider’s stock worth $7,935,000 after buying an additional 11,893 shares during the last quarter. First Trust Advisors LP bought a new stake in Nevro during the second quarter worth about $1,631,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in Nevro during the second quarter worth about $725,000.
Nevro Corp. (NYSE NVRO) traded up $1.94 on Thursday, hitting $68.20. 429,000 shares of the stock traded hands, compared to its average volume of 513,340. Nevro Corp. has a twelve month low of $65.00 and a twelve month high of $99.63. The company has a current ratio of 8.78, a quick ratio of 6.81 and a debt-to-equity ratio of 0.59.
Nevro (NYSE:NVRO) last announced its quarterly earnings data on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.02. Nevro had a negative net margin of 14.09% and a negative return on equity of 17.27%. The business had revenue of $82.26 million for the quarter, compared to analyst estimates of $80.50 million. During the same period in the prior year, the business posted ($0.14) earnings per share. Nevro’s revenue was up 35.0% compared to the same quarter last year. equities analysts anticipate that Nevro Corp. will post -1.27 EPS for the current fiscal year.
Several analysts have weighed in on NVRO shares. Zacks Investment Research raised shares of Nevro from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. BidaskClub cut shares of Nevro from a “hold” rating to a “sell” rating in a research note on Saturday, October 28th. TheStreet raised shares of Nevro from a “d+” rating to a “c-” rating in a research note on Monday, November 6th. Canaccord Genuity decreased their price target on shares of Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, November 7th. Finally, Leerink Swann reissued an “outperform” rating and set a $110.00 price target (up from $105.00) on shares of Nevro in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $99.25.
In related news, CFO Andrew H. Galligan sold 7,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total value of $525,770.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael F. Demane sold 5,000 shares of the stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $93.50, for a total transaction of $467,500.00. The disclosure for this sale can be found here. Insiders sold 17,000 shares of company stock worth $1,450,770 over the last 90 days. 12.10% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Janus Henderson Group PLC Has $113.54 Million Position in Nevro Corp. (NVRO)” was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.truebluetribune.com/2017/12/14/janus-henderson-group-plc-has-113-54-million-position-in-nevro-corp-nvro.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.